HealthTree Logo
search more_vert
close
person Sign In / Create Account
Extending Outcomes with Continuous Myeloma Maintenance: Dr. Antonio Palumbo, MD, University of Torino
Extending Outcomes with Continuous Myeloma Maintenance: Dr. Antonio Palumbo, MD, University of Torino image
HealthTree Podcast for Multiple Myeloma
event Aug 25, 2014 / 11:00AM MDT

Event Description

Learn about all myeloma happenings on the new Myeloma Crowd site: the first comprehensive site for myeloma patients and caregivers. Dr. Antonio Palumbo, MD University of Torino, Italy Interview Date: August 25, 2014

 Dr. Antonio Palumbo, MD of the University of Torino, Italy discusses his ASCO 2014 findings showing that continuous maintenance therapy can give on average an additional year of benefit for most myeloma patients. He notes that if patients have minimal residual disease, that continuing maintenance can help keep the myeloma down, improving their remission status over time. He cautions that even though patients may achieve a stringent complete response, it doesn't mean they are disease-free because there is always residual tumor. He wondered if giving continuous maintenance after the first remission would negate any benefit by making the myeloma come back in the second remission more aggressively, but found this wasn't the case;  it still provided a year of benefit. He shares that only about 20% of patients will become refractory to the treatment with extended use. Dr. Palumbo describes when to stop continuous maintenance - when toxicities are above a grade 1 or whenever the patient feels that they are too much for an acceptable quality of life. Dr. Palumbo shares that Revlimid and bortezomib have been used as maintenance and both have shown the year benefit, although there have been no head-to-head comparisons between the two. He notes that out of all the indicators that may influence outcomes like disease biology and the patient response, the best indicator for outcomes is the duration of response. If patients have a longer response, they will have better overall outcomes regardless of remission status. He describes that with the wide variety of newer myeloma treatments, patients are now having not one or two remissions, but four, five or six remissions and while this is great news for patients, it makes understanding the impact of continuous maintenance more complicated to calculate. The live mPatient Myeloma Radio podcast with Dr. Antonio Palumbo, MD

Schedule & Agenda

person
Discussion
11:00AM
Dr. Antonio Palumbo & Jennifer Ahlstrom

Speakers & Moderators

The panelist Jennifer Ahlstrom
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

1-800-709-1113

email

Support@healthtree.org

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Johnson and Johnson
Sanofi
Pfizer
Regeneron
Adaptive
Bristol Myers Squibb

Follow Us

facebook instagram linkedin tiktok youtube